Literature DB >> 24473414

Tipping the balance in favour of degarelix for ADT.

Melanie Clyne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24473414     DOI： 10.1038/nrurol.2014.11

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.

Authors:  Laurence Klotz; Kurt Miller; E David Crawford; Neal Shore; Bertrand Tombal; Cathrina Karup; Anders Malmberg; Bo-Eric Persson
Journal:  Eur Urol       Date:  2014-01-09       Impact factor: 20.096
  1 in total
  1 in total

1.  Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases.

Authors:  Gincy George; Lucie-Marie Scailteux; Hans Garmo; Frédéric Balusson; Christopher Cardwell; Greet De Coster; Harlinde De Schutter; Josephina G Kuiper; Úna McMenamin; Julie Verbeeck; Mieke Van Hemelrijck
Journal:  Fundam Clin Pharmacol       Date:  2019-03-25       Impact factor: 2.748
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.